Inventor · disambiguated record
Philippe Duchateau
Also filed as: DUCHATEAU PHILIPPE
52 granted patents·54 pending applications·345 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
106 records- 0198US10584352B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2018·Granted Mar 10, 2020·21 cites·20 claims
- 0298US9855297B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2016·Granted Jan 2, 2018·50 cites·17 claims
- 0397US10870864B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Dec 22, 2020·4 cites·18 claims
- 0497US9890393B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2014·Granted Feb 13, 2018·38 cites·3 claims
- 0595US7897372B2I-CreI meganuclease variants with modified specificity, method of preparation and uses thereofCELLECTIS·Filed 2006·Granted Mar 1, 2011·42 cites·54 claims
- 0695US7842489B2Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS·Filed 2010·Granted Nov 30, 2010·63 cites·7 claims
- 0793US10196608B2Method for in situ inhibition of regulatory T cellsCELLECTIS·Filed 2015·Granted Feb 5, 2019·8 cites·16 claims
- 0892US10836998B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2015·Granted Nov 17, 2020·5 cites·26 claims
- 0992US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 1091US8530214B2Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofARNOULD SYLVAIN·Filed 2011·Granted Sep 10, 2013·13 cites·16 claims
- 1189US11186824B2Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patientsCELLECTIS·Filed 2016·Granted Nov 30, 2021·4 cites·22 claims
- 1289US10239948B2Method of engineering multi-input signal sensitive T cell for immunotherapyCELLECTIS·Filed 2014·Granted Mar 26, 2019·16 cites·9 claims
- 1388US11690873B2Universal chimeric antigen receptor T cells specific for CD22CELLECTIS SA·Filed 2018·Granted Jul 4, 2023·4 cites·20 claims
- 1487US10815500B2Transcription activator-like effector (TALE) fusion proteinJUILLERAT ALEXANDRE·Filed 2013·Granted Oct 27, 2020·13 cites·12 claims
- 1587US9315788B2Method for the generation of compact TALE-nucleases and uses thereofDUCHATEAU PHILIPPE·Filed 2012·Granted Apr 19, 2016·12 cites·33 claims
- 1686US12252699B2Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2023·Granted Mar 18, 2025·0 cites·12 claims
- 1785US11466291B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2017·Granted Oct 11, 2022·4 cites·27 claims
- 1885US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 1985US10472613B2Method for modulating car-induced immune cells activityCELLECTIS·Filed 2015·Granted Nov 12, 2019·6 cites·29 claims
- 2085US10301614B2Method to overcome DNA chemical modifications sensitivity of engineered tale DNA binding domainsCELLECTIS SA·Filed 2013·Granted May 28, 2019·4 cites·16 claims
- 2184US11944643B2Universal anti-CD22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2018·Granted Apr 2, 2024·2 cites·12 claims
- 2282US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 2381US10087453B2Modified diatoms for biofuel productionCELLECTIS·Filed 2014·Granted Oct 2, 2018·4 cites·20 claims
- 2480US12391933B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2023·Granted Aug 19, 2025·0 cites·15 claims
- 2580US8906607B2Method for modulating double-strand break-induced homologous recombinationDUCHATEAU PHILIPPE·Filed 2010·Granted Dec 9, 2014·5 cites·19 claims
- 2679US11674155B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2022·Granted Jun 13, 2023·0 cites·17 claims
- 2778US2023357719A1Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 2877US10508289B2Rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motivesCELLECTIS SA·Filed 2014·Granted Dec 17, 2019·3 cites·6 claims
- 2976US2023287454A1Sequential gene editing in primary immune cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 3075US11959091B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Apr 16, 2024·0 cites·21 claims
- 3175US2025277231A1Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2025·Application pending·0 cites
- 3274US8715992B2I-CreI meganuclease variants with modified specificity, method of preparation and uses thereofDUCHATEAU PHILIPPE·Filed 2012·Granted May 6, 2014·2 cites·5 claims
- 3374US2022010292A1Method for the generation of compact tale-nucleases and uses thereofCELLECTIS·Filed 2021·Application pending·0 cites
- 3474US2024228636A1mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLSCELLECTIS·Filed 2023·Application pending·0 cites
- 3573US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 3672US11365430B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Jun 21, 2022·0 cites·20 claims
- 3772US11136566B2Tale-protein scaffolds and uses thereofCELLECTIS·Filed 2019·Granted Oct 5, 2021·0 cites·17 claims
- 3872US2025034641A1Cellular immunotherapy for repetitive administrationCELLECTIS·Filed 2024·Application pending·0 cites
- 3971US11820996B2Method for generating T-cells compatible for allogenic transplantationCELLECTIS·Filed 2018·Granted Nov 21, 2023·0 cites·14 claims
- 4071US11692169B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2020·Granted Jul 4, 2023·0 cites·18 claims
- 4171US9044492B2Method for modulating the efficiency of double-strand break-induced mutagenesisDELACOTE FABIEN·Filed 2012·Granted Jun 2, 2015·2 cites·9 claims
- 4267US10526406B2Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fishCELLECTIS·Filed 2015·Granted Jan 7, 2020·1 cites·6 claims
- 4366US11220683B2Method to overcome DNA chemical modifications sensitivity of engineered TALE DNA binding domainsCELLECTIS·Filed 2019·Granted Jan 11, 2022·0 cites·20 claims
- 4466US2025281613A1Enhancing safety of t-cell-mediated immunotherapyCELLECTIS SA·Filed 2023·Application pending·0 cites
- 4563US2016122774A1A method for producing precise dna cleavage using cas9 nickase activityCELLECTIS·Filed 2014·Application pending·0 cites
- 4663US2025057952A1Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumorsCELLECTIS SA·Filed 2022·Application pending·0 cites
- 4762US11198856B2Method for the generation of compact tale-nucleases and uses thereofCELLECTIS·Filed 2016·Granted Dec 14, 2021·0 cites·22 claims
- 4862US2025288673A1Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)CELLECTIS SA·Filed 2023·Application pending·0 cites
- 4962US2013203840A1Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS SA·Filed 2012·Application pending·0 cites
- 5061US2024318154A1Gene therapy for the treatment of severe combined immunodeficiency (scid) related to rag1CELLECTIS·Filed 2022·Application pending·0 cites
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Philippe Duchateau files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →